Human IL-2 receptor β mutations associated with defects in immunity and peripheral tolerance
Authors:
- Zinan ZhangZZZinan Zhang
- Florian GotheFGFlorian Gothe
- Perrine PennamenPPPerrine Pennamen
- John JamesJJJohn James
- David MacDonaldDMDavid MacDonald
- Carlos P. MataCMCarlos P. Mata
- Yorgo ModisYMYorgo Modis
- Meghan AcresMAMeghan Acres
- Wolfram HallerWHWolfram Haller
- Claire BowenCBClaire Bowen
- Rainer DoffingerRDRainer Doffinger
- Jan SinclairJSJan Sinclair
Preprint
Abstract
Interleukin-2, which conveys essential signals for effective immunity and immunological tolerance, operates through a heterotrimeric receptor comprised of α, β and γ chains. Genetic deficiency of the α or γ chain causes debilitating disease. Here we identify human interleukin-2 receptor (IL-2R) β chain (CD122) gene defects as a cause of life-threatening dysregulation of immunity and peripheral tolerance. We report homozygous mutations in the human IL-2Rβ gene from four consanguineous families, comprising either recessive missense mutations in five children or an early stop-gain mutation in two deceased fetuses and a premature neonate. All patients surviving to childhood presented with autoantibodies, hypergammaglobulinemia, bowel inflammation, and dermatological abnormalities, as well as cytomegalovirus disease in most cases. Patient T lymphocytes lacked surface expression of IL-2Rβ and were unable to normally respond to high-dose IL-2 stimulation. By contrast, patient natural killer (NK) cells retained partial IL-2Rβ expression and cytotoxic function. IL-2Rβ loss of function was recapitulated in a recombinant system, in which endoplasmic reticulum sequestration was revealed as the mechanism by which certain missense mutations cause disease. Hematopoietic stem cell transplant resulted in resolution of clinical symptoms in one patient. The hypomorphic nature of this disease highlights the significance of variable IL-2Rβ expression in different lymphocyte subsets as a means of modulating immune function. Insights from these patients can inform the development of IL-2-based therapeutics for immunological diseases and cancer.Keywords
All Related Versions
- Published version: Journal of Experimental Medicine, 216 (6), 1311.
This publication has 26 references indexed in Scilit:
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokinesOncoImmunology, 2017
- GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputersSoftwareX, 2015
- Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritisNature Genetics, 2013
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and ImmunotherapyImmunity, 2013
- Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironmentsProceedings of the National Academy of Sciences, 2010
- CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked–like syndrome, and defective IL-10 expression from CD4 lymphocytesJournal of Allergy and Clinical Immunology, 2007
- Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune ComplexesScience, 2006
- IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patientsBlood, 2006
- A function for interleukin 2 in Foxp3-expressing regulatory T cellsNature Immunology, 2005
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004